Register Login

EDWARDS LIFESCIENCES CORP (EW)

Director Zovighian Bernard J 🟡 adjusted position in 62.5K shares (1 derivative) of Edwards Lifesciences Corp (EW) at $79.96 ($4.9M) Transaction Date: May 11, 2026 | Filing ID: 005172

Full text
Register to leave comments
  • News bot May 12, 2026, 8:56 p.m.

    🔍 Zovighian Bernard J (Director)

    Company: Edwards Lifesciences Corp (EW)

    Report Date: 2026-05-11

    Transaction Summary:

    • Total transactions: 8
    • Derivative instruments: 1
    • Holdings reported: 1
    • Total shares acquired: 73,847
    • Total shares sold: 136,396
    • Total shares held: 3,734

    Detailed Transactions and Holdings:

    • Acquired 47,207 shares of Common Stock (Direct)
      Date: 2026-05-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 157,491.65 | transaction_form_type: 4 | Footnotes: F1, F1
    • Sold 26,198 shares of Common Stock at $79.96 per share (Direct)
      Date: 2026-05-11 | Code: F | equity_swap_involved: 0 | shares_owned_after: 125,804.65 | transaction_form_type: 4
    • Sold 26,640 shares of Common Stock (Direct)
      Date: 2026-05-12 | Code: G | equity_swap_involved: 0 | shares_owned_after: 99,164.65 | transaction_form_type: 4
    • Acquired 26,640 shares of Common Stock (Direct)
      Date: 2026-05-12 | Code: G | equity_swap_involved: 0 | shares_owned_after: 48,390.55 | transaction_form_type: 4
    • Sold 845 shares of Common Stock at $78.4027 per share (Direct)
      Date: 2026-05-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 47,545.55 | transaction_form_type: 4 | Footnotes: F2, F3
    • Sold 35,506 shares of Common Stock at $77.9238 per share (Direct)
      Date: 2026-05-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,039.55 | transaction_form_type: 4 | Footnotes: F2, F4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-05-11 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 3,733.56
    • Sold 47,207 shares of Performance Rights (Derivative)
      Date: 2026-05-11 | Code: M | Exercise: 2026-05-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F5

    Footnotes:

    • F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
    • F2: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
    • F3: This transaction was executed in multiple trades at prices ranging from $78.390 to $78.430. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
    • F4: This transaction was executed in multiple trades at prices ranging from $77.375 to $78.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
    • F5: These Performance Rights expire on May 10, 2030.
    • REMARKS: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Search

News categories